GSK posts mixed survival data for Jemperli/Zejula combo in first-line ovarian cancer

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the third quarter.
GSK on Friday unveiled headline findings from the Phase III FIRST-ENGOT-OV44 study, posting mixed survival results for add-on Jemperli to standard-of-care chemotherapy and Zejula in patients with advanced ovarian cancer.